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In higher eukaryotic organisms, the checkpoint kinase 1 (Chk1) contributes essential functions to both cell
cycle and checkpoint control. Chk1 executes these functions, in part, by targeting the Cdc25A protein phos-
phatase for ubiquitin-mediated proteolysis. In response to genotoxic stress, Chk1 is phosphorylated on serines
317 (S317) and 345 (S345) by the ataxia-telangiectasia-related (ATR) protein kinase. Phosphorylation of Chk1
on these C-terminal serine residues is used as an indicator of Chk1 activation in vivo. Here, we report that
inhibition of Chk1 kinase activity paradoxically leads to the accumulation of S317- and S345-phosphorylated
Chk1 in vivo and that ATR catalyzes Chk1 phosphorylation under these conditions. We demonstrate that Chk1
phosphorylation by ATR is antagonized by protein phosphatase 2A (PP2A). Importantly, dephosphorylation
of Chk1 by PP2A is regulated, in part, by the kinase activity of Chk1. We propose that the ATR-Chk1-PP2A
regulatory circuit functions to keep Chk1 in a low-activity state during an unperturbed cell division cycle
but at the same time keeps Chk1 primed to respond rapidly in the event that cells encounter genotoxic
stress.
Reversible phosphorylation contributes to cellular homeo-
stasis by regulating such diverse biological processes as traf-
ficking, signaling, proliferation, and cell division (4, 10, 23, 33).
In human cells, reversible phosphorylation relies on the antag-
onistic activities of over 500 protein kinases and approximately
180 protein phosphatases (4, 34). Checkpoint kinase 1 (Chk1)
is a serine/threonine protein kinase that is also regulated by
reversible phosphorylation. Chk1 was first identified in fission
yeast as an essential component of the DNA damage check-
point (3, 45). Although Chk1 is not required for vegetative
growth in fission yeast, it is an essential gene in mice (31, 44).
A role for Chk1 in genome surveillance during DNA replica-
tion may explain why disruption of Chk1 results in early em-
bryonic lethality in mice.
In higher eukaryotic organisms, Chk1 regulates the timing
and fidelity of cell cycle transitions, in part, by regulating the
Cdc25A protein phosphatase (28, 41, 42, 51). Chk1-mediated
phosphorylation of Cdc25A serves at least two functions. One
is to target Cdc25A for ubiquitin-mediated proteolysis, and the
second is to regulate interactions between Cdc25A and Cdk1/
cyclin B1 complexes (8, 15, 18, 22, 42, 51). Cdc25A accumu-
lates in cells treated with either Chk1 inhibitors or Chk1-
specific small interfering RNAs (siRNAs) (42, 47, 51).
Importantly, loss of Chk1 function not only results in Cdc25A
accumulation but also causes cells to bypass the DNA damage
and DNA replication checkpoints (42, 47, 51).
In response to DNA damage or replication stress, human
Chk1 becomes phosphorylated on two residues within its C
terminus (serines 317 and 345) (31, 50). Studies conducted in
Xenopus egg extracts and cultured human cells indicate that
Chk1 is directly phosphorylated on these residues by the ataxia-
telangiectasia-related (ATR) protein kinase (17, 21, 24, 31,
50), and C-terminal phosphorylation has been proposed to
activate Chk1 by relieving autoinhibition (26, 37).
Three serine/threonine protein phosphatases have been
implicated in dephosphorylating Chk1 on S317 and S345. In
fission yeast, the type I protein phosphatase homolog Dis2
dephosphorylates S345 (13), whereas in human cells, the p53-
regulated protein phosphatase Wip1 (PPM1D) dephosphorylates
activated Chk1 on S345 in response to UV damage (32). Further-
more, protein phosphatase 2A (PP2A) can dephosphorylate Xen-
opus Chk1 on S344 (homologous to S345 of human Chk1) in
extracts in vitro (38). Here we demonstrate that human Chk1
is maintained in a hypophosphorylated state during the S and
G2 phases of the cell division cycle through the antagonistic
activities of ATR and PP2A.
MATERIALS AND METHODS
Cell lines. HeLa cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS) or bovine
growth serum (HyClone), 100 U/ml penicillin and streptomycin, and 1 mM
glutamine. AT22IJE T cells expressing ataxia-telangiectasia mutated protein
(ATM) (AT) or not expressing ATM (AT) (52) were cultured in DMEM
supplemented with 10% fetal bovine serum, 100 U/ml of penicillin and strepto-
mycin, 1 mM glutamine, and 100 g/ml of hygromycin.
Chemicals and drugs. Hydroxyurea (HU), wortmannin, and okadaic acid
(OA) were purchased from Sigma Chemical Co. VP-16, fostriecin, Go¨6976, and
SB-218078 were purchased from Calbiochem. UCN-01 (NSC 638850) was kindly
provided by Jill Johnson (Drug Synthesis and Chemistry Branch, NCI, National
Institutes of Health). Inhibitor 2 (I-2) was purchased from New England Biolabs.
Plasmids. The pEGFP-Chk1 wild-type (WT) construct was generated by in-
serting Chk1 cDNA at the XhoI site in pEGFP-C1 (Clontech). The pEGFP-
Chk1 kinase-inactive mutant (D130A) was generated by using the pEGFP-Chk1
WT as a template; the mutation was introduced as described previously (50).
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Antibodies. Chk1 was detected with rabbit polyclonal (FL-476; Santa Cruz
Biotechnology) or mouse monoclonal (G-4; Santa Cruz Biotechnology) antibod-
ies. Antibodies specific for phosphorylated Chk1, anti-phospho Akt, anti-Akt,
and anti-phospho ATM/ATR substrate were purchased from Cell Signaling
Technology. Other primary antibodies used were anti-Cdc25A (Ab-3; Neomar-
kers), anti-phospho Smc1 S966 (Novus Biologicals), anti-phospho Brca1 S1423
(Chemicon), anti-PP1 (Upstate), anti-PP2A (Upstate), anti-PP4 (recognizes
PP2A and PP4) (Abcam), anti-PP6 (Exalpha Biologicals), anti--catenin (BD
Transduction), anti-H2AX (Upstate), anti-ATR (Oncogene), and anti-p1981-
ATM (Rockland Biochemicals). Bound primary antibodies were detected with
either horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody
(Jackson ImmunoResearch) or HRP-conjugated rat anti-rabbit antibody
(Zymed), and proteins were visualized by chemiluminescence.
Cell synchrony and in vivo treatment with chemical inhibitors. HeLa cells
were synchronized using a double-thymidine block-and-release protocol as de-
scribed previously (8). Cells were released from the block and were incubated
with dimethyl sulfoxide (DMSO), Go¨6976, SB-218078, or UCN-01 as they en-
tered different phases of the cell cycle. Cells were either analyzed by flow
cytometry (11) or were lysed in MCLB (50 mM Tris-HCl, pH 8.0, 100 mM NaCl,
5 mM EDTA, 0.5% Nonidet P-40, and 2 mM dithiothreitol [DTT]) containing 1
mM sodium orthovanadate, 10 mM -glycerophosphate, 1 M microcystin, 2
mM phenylmethylsulfonyl fluoride (PMSF), 10 g/ml of aprotinin, and 5 g/ml
of leupeptin and analyzed by Western blotting. Alternatively, asynchronously
growing HeLa cells were incubated in culture medium containing either 20 mM
HU, 20 M VP-16, 50 M wortmannin, 1 M OA, or 0.03 to 1 M Go¨6976 for
the times indicated in the figure legends and harvested in MCLB for Western
blot analysis. In addition, AT and AT cells were treated with or without 1 M
Go¨6976 for 1 or 2 h before being lysed in MCLB. For dephosphorylation
experiments, phosphatase inhibitors were left out of the lysis buffer.
Treatment of cell lysates with inhibitors. HeLa cell cultures were lysed in
MCLB. Clarified lysates were collected at two time points with an initial aliquot
collected immediately after lysis and kept on ice. The remaining fractions were
incubated with the different phosphatase inhibitors or Go¨6976 for 30 min at
30°C. The concentrations of inhibitors were as follows: 1 M OA, 0.5 M
fostriecin, 1 M I-2, and 1 M Go¨6976.
Chk1 dephosphorylation in vivo. HeLa cells were treated with 20 mM HU for
2 h to increase phosphorylated Chk1, washed twice with phosphate-buffered
saline (PBS), and cultured in complete DMEM. Samples were collected at
different time points after HU removal in the absence or presence of chemical
inhibitors. Phosphorylation of Chk1 was assessed by Western blotting.
RNAi treatment. The knockdown of ATR was accomplished with an ATR-
specific siRNA with the sequence 5-AACUGACUCUCAGCCAACCUC-3.
Approximately 2  105 HeLa cells were seeded per well in six-well dishes the day
before transfection. Transfection was performed using Oligofectamine (Invitro-
gen) according to the manufacturer’s instructions. The final siRNA concentra-
tion was 100 nM. Forty-eight hours posttransfection, cells were treated with or
without 1 M Go¨6976 for 2 h and harvested in MCLB. Lysates were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to nitrocellulose. The resulting membranes were blotted with the
indicated antibodies. Proteins were visualized and quantified using the ECL
enhanced chemiluminescence reagent (Amersham), which contains a chemifluo-
rescence component for quantification on a Molecular Dynamics Storm Imager
(Molecular Biosystems, Piscataway, NJ). To knockdown PP2A and PP1, approx-
imately 2  105 HeLa cells were seeded per well in six-well dishes. The next day,
cells were transfected with Smartpool siRNA (Dharmacon) against the specific
phosphatases using Dharmafect 2 reagent (Dharmacon) according to the man-
ufacturer’s instructions. The final siRNA concentration was 100 nM. Forty-eight
hours later, cells were treated with or without 1 M Go¨6976 for 1 h and
harvested in MCLB. Lysates were analyzed by immunoblotting or were used to
dephosphorylate ectopic green fluorescent protein (GFP)-Chk1 (see below). The
Smartpool reagents were the scrambled control (D00121002), PP1 (M00892700),
and PP2A (M00359800 and M00359902).
Chk1 dephosphorylation in vitro. To generate substrate for phosphatase re-
actions, approximately 2  106 HeLa cells per 100-mm dish were seeded and
transfected the next day with 10 g of pEGFP-Chk1 WT using Lipofectamine
2000 (Invitrogen), according to the manufacturer’s instructions. One day after
transfection, cells were treated with 20 mM HU for 2 h to induce phosphoryla-
tion of GFP-Chk1. Cells were lysed in PBS lysis buffer (137 mM NaCl, 2.7 mM
KCl, 4.3 mM Na2HPO4 · 7H2O, 1.4 mM KH2PO4, 0.5% Nonidet P-40, and 2 mM
DTT) containing 2 mM phenylmethylsulfonyl fluoride (PMSF), 10 g/ml of
aprotinin, and 5 g/ml of leupeptin. Phosphorylated GFP-Chk1 was immuno-
precipitated using 20 l of prewashed anti-GFP beads (MBL International) at
4°C for 2 h. Immunoprecipitated GFP-Chk1 was washed five times with PBS lysis
buffer, twice with LiCl buffer (0.5 M LiCl, 50 mM Tris, pH 8), and twice with
phosphatase buffer (50 mM Tris, pH 7, 0.1 mM CaCl2, 1 mM MnCl2) and
resuspended in phosphatase buffer. For dephosphorylation in siRNA-treated cell
lysates, 20 l of GFP-Chk1 substrate was added to 200 g of lysate in MCLB
buffer. Dephosphorylation reactions were performed at 30°C for 30 min. For in
vitro phosphatase reactions, 20 l of GFP-Chk1 substrate was incubated with 100
ng of purified PP1 or PP2A (Sigma-Aldrich Co.) for 30 min at 30°C in the
presence or absence of chemical inhibitors. Dephosphorylation of GFP-Chk1
was analyzed by Western blotting.
Flow cytometry. HeLa cells were harvested by trypsinization and collected by
centrifugation. Cells were washed once with PBS and fixed in 5 ml of 70%
ethanol at 4°C. Cells were washed once with PBS–1% bovine serum albumin
(BSA) and then incubated with 1 ml of PBS–1% BSA containing 30 g/ml
propidium iodide (PI) and 0.25 mg/ml RNase A for 1 h at room temperature.
Cells were analyzed for DNA content by flow cytometry using a FACS Calibur
fluorescence-activated cell sorter (BD Biosciences). For experiments using
pEGFP plasmids, only GFP-positive cells were analyzed for DNA content. To
gate on GFP-positive cells, untransfected cells stained with PI were analyzed first
and located at less than 101 on the x axis (FL-1 channel) in histograms. Trans-
fected cells were then analyzed and DNA content was determined on cell pop-
ulations that located greater than 101 on the x axis in histograms. The data were
analyzed using CellQuest analysis software (BD Biosciences).
Indirect immunofluorescence. HeLa cells were cultured on glass coverslips
and treated as indicated in the figure legends. Cells were fixed in ice-cold 100%
methanol at 20°C for 15 min and permeabilized with ice-cold acetone for 30 s.
Cells were incubated in blocking solution (PBS–1% BSA) for 1 h at room
temperature and then incubated with anti-H2AX at 1:400 for 2 h at room
temperature. Cells were washed five times in washing solution (PBS–1% BSA),
incubated in fluorescein isothiocyanate (FITC)-labeled goat anti-mouse second-
ary antibody (Molecular Probes) for 1 h at room temperature, and then washed
five more times. Images were obtained using a confocal laser-scanning micro-
scope (MRC 1024; Bio-Rad).
RESULTS
Chk1 inhibitors induce Chk1 phosphorylation on S317 and
S345. Genotoxic stress activates a protein kinase-signaling cas-
cade that initiates with the ATM and ATR protein kinases and
ultimately signals to the Chk1 protein kinase (25, 40). ATR
directly phosphorylates Chk1 and, depending on the type of
genotoxic stress encountered, Chk1 phosphorylation by ATR is
either ATM dependent or independent (1, 24, 31, 50). Chk1
residues phosphorylated by ATM/ATR include S317 and S345,
and phosphorylation of Chk1 on these C-terminal residues is
used to monitor the activation state of Chk1 in vivo (31, 50).
Thus, it was surprising to observe that incubation of cells with
three different Chk1 inhibitors, UCN-01 (7, 20), Go¨6976 (29),
and SB-218078 (12), caused Chk1 to accumulate in an S317/
S345-phosphorylated (presumably active) form (Fig. 1). The
accumulation of Cdc25A in cells treated with each Chk1 in-
hibitor indicated that the inhibitors blocked Chk1 function in
vivo (Fig. 1A and B). The phosphorylation of Chk1 on S317
and S345 was observed within 15 min of drug addition and
peaked after 90 min in asynchronously growing cells (Fig. 1A).
The ability of Chk1 inhibitors to induce Chk1 phosphorylation
was greatest in the S and G2 phases of the cell cycle (Fig. 1C).
Importantly, Go¨6976 does not detectably alter the cell cycle
distribution of treated cells, demonstrating that the alterations
in Chk1 phosphorylation reported in this study are not due to
indirect effects of Chk1 inhibitors on the cell division cycle (see
Table S1 in the supplemental material).
ATR mediates Chk1 phosphorylation in presence of Chk1
inhibitors. Several approaches were taken to determine if
ATM and/or ATR was required for Chk1 phosphorylation
under these conditions (Fig. 2). The ability of the Chk1 inhib-
itor Go¨6976 to induce phosphorylation of Chk1 on S345 was
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reduced in cells pretreated with wortmannin (Fig. 2A, lane 4),
a phosphatidylinositol 3-kinase inhibitor that inhibits ATM,
DNA protein kinase, and ATR (39). Go¨6976 also effectively
induced Chk1 S345 phosphorylation in cells lacking functional
ATM (Fig. 2B, lanes 5 and 6), demonstrating that ATM is not
necessary for induction of Chk1 phosphorylation in vivo by
Go¨6976. Finally, partial knockdown of ATR reduced Chk1
S345 phosphorylation by 40% in Go¨6976-treated cells (Fig. 2C,
lane 4). Taken together, these results indicate that ATR con-
tributes to Chk1 phosphorylation in cells treated with Chk1
inhibitors.
Chk1 inhibitors do not detectably activate ATR or induce
H2AX foci. One explanation to account for these results is
that Chk1 inhibitors directly or indirectly activate ATR to
promote Chk1 phosphorylation in vivo. To test this possibility,
the phosphorylation statuses of general and specific ATR sub-
strates were monitored in cells treated with Go¨6976 (Fig. 3).
As positive controls, cells were treated with VP-16 to activate
ATM or with HU to activate ATR. As seen in Fig. 3A (lane 2),
Go¨6976 did not induce phosphorylation of substrates seen in
cells with activated ATM (lane 3) or ATR (lane 4). Nor did
Go¨6976 treatment induce significant phosphorylation of the
ATM/ATR substrates Brca1 (Fig. 3B) and Smc1 (Fig. 3C).
Finally, phosphorylation of ATM on S1981 (5) was not ob-
served in Go¨6976-treated cells (Fig. 3C).
A previous study conducted with U2OS cells reported that
Chk1 inhibition activates a DNA damage checkpoint response,
as indicated by phosphorylation of the histone variant H2AX,
and this, in turn, induced Chk1 phosphorylation (43). Thus, we
monitored for the appearance of phosphorylated H2AX
(H2AX) at discrete nuclear foci in Go¨6976-treated cells be-
cause this is one of the earliest events observed in cells with
DNA double-strand breaks (DSBs). As seen in Fig. 3D,
H2AX foci were readily detected in cells treated with VP-16
or HU. In contrast, incubation of cells with Go¨6976 for 1 or 2 h
did not increase the number of H2AX foci relative to control
cells. However, an increase in the number of H2AX foci was
observed in cells treated with Go¨6976 for longer periods (6 h).
Thus, the rapid phosphorylation of Chk1 on S317 and S345
following Chk1 inhibition is not accounted for by activation of
a DNA damage checkpoint response in HeLa cells.
Chk1 inhibitors impair Chk1 dephosphorylation in vivo but
not in vitro. Given that Chk1 inhibitors do not induce signifi-
cant ATR activation in HeLa cells, we next asked whether they
impair Chk1 dephosphorylation. Cells were treated with HU to
enrich for phosphorylated Chk1. HU was then removed, and
Chk1 dephosphorylation on S317 and S345 was monitored in
vivo. As seen in Fig. 4A, dephosphorylation of S317 and S345
occurred in a time-dependent manner in control cells treated
with DMSO (lanes 3 and 4). Importantly, incubation of cells
FIG. 1. Chk1 inhibitors induce Chk1 phosphorylation on S317 and S345 in vivo. (A) Asynchronously growing HeLa cells were treated with
either vehicle (DMSO) or 1 M Go¨6976 for the indicated times. Western blotting was performed with the indicated antibodies. (B) HeLa cells,
synchronized by a double-thymidine-block protocol, were released into S phase and treated with different concentrations of either UCN-01,
SB-218078, or Go¨6976 for 1.5 h. Total lysates were probed with antibodies specific for Cdc25A, phosphorylated Chk1 (pS345), total Chk1, and
-catenin. Controls included asynchronously growing cells (Asy), cells treated with the vehicle DMSO (V), and cells collected at 0 h before release
(G1/S). The asterisk indicates phosphorylated Chk1. (C) HeLa cells synchronized by a double-thymidine-block protocol were released and
harvested at the indicated times: 1.5 h (S phase), 3 h 45 min (G2 phase), and 10 h 50 min (G1 phase). In addition, nocadazole was added for 10 h
50 min after release to collect M-phase cells. DMSO, SB-218078, or Go¨6976 (5 M) was added 1.5 h prior to harvest of cells at each cell cycle
stage. Total lysates were prepared and analyzed by Western blotting.
VOL. 26, 2006 ATR-Chk1-PP2A REGULATORY CIRCUIT 7531
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with the Chk1 inhibitor Go¨6976 subsequent to HU removal
impaired S317 and S345 dephosphorylation (lanes 5 and 6) as
did incubation with the phosphatase inhibitor OA (lanes 7 and
8). Chk1 dephosphorylation was maximally inhibited in vivo at
Go¨6976 concentrations between 0.3 and 1 M (see Fig. S1A in
the supplemental material).
Interestingly, treatment of cells with OA alone (Fig. 4A, lane
11), like Go¨6976 (lane 10), resulted in the accumulation of
phosphorylated Chk1 in vivo.
To determine whether Go¨6976 functions to inhibit the phos-
phatase or phosphatases that dephosphorylate Chk1 on S317
and S345, the dephosphorylation of Chk1 was monitored in
cell lysates in vitro (Fig. 4B). Lysates were incubated with
DMSO, Go¨6976, or OA, and the phosphorylation status of
endogenous Chk1 was monitored after a 30-min incubation
period. OA at a concentration of 10 nM effectively blocked
Chk1 dephosphorylation in vitro (lane 8). In contrast, Go¨6976
did not prevent Chk1 dephosphorylation in vitro even at con-
centrations of 2 M (lane 6). These results demonstrate that
the Chk1 inhibitors do not directly inhibit the phosphatase(s)
responsible for dephosphorylating Chk1 on S317 and S345 and
that the Chk1 phosphatase(s) may be OA sensitive.
Chk1 kinase activity positively regulates Chk1 dephosphor-
ylation. Taken together, these results demonstrate that the
Chk1 inhibitors do not function by directly stimulating Chk1
phosphorylation or by directly inhibiting Chk1 dephosphoryla-
tion. Another model that accounts for the data is that Chk1 is
continually being phosphorylated on S317 and S345 in vivo and
at the same time Chk1 promotes its own dephosphorylation. In
this case, inhibition of Chk1 kinase activity would result in a
net reduction in Chk1 dephosphorylation and by default a net
increase in phosphorylated Chk1. This model predicts that
levels of phosphorylated kinase-inactive Chk1 would be higher
than levels of phosphorylated kinase-active Chk1 because ki-
nase-inactive Chk1 would be incapable of stimulating its own
dephosphorylation. As seen in Fig. 5A, kinase-inactive Chk1
(lane 6) was more highly phosphorylated on S345 than was
wild-type Chk1 (lane 1) under basal conditions. This model
also predicts that dephosphorylation of kinase-inactive Chk1
might occur more slowly than dephosphorylation of wild-type
Chk1 in vivo. To test this, cells expressing wild-type or kinase-
inactive GFP-Chk1 were treated with HU to induce phosphor-
ylation of Chk1. HU was then removed to allow Chk1 dephos-
phorylation to occur in vivo. The phosphorylation status of
Chk1 was monitored at various times after HU removal. As
seen in Fig. 5A, dephosphorylation of wild-type Chk1 (lanes 2
to 5) occurred more quickly than did dephosphorylation of
kinase-inactive Chk1 (lanes 7 to 10). FACS analysis revealed
that the cell cycle distributions of cells expressing kinase-active
and -inactive forms of Chk1 were similar (Fig. 5B). Thus, the
differences in phosphorylation observed between kinase-active
and -inactive forms of Chk1 cannot be attributed to cell cycle
differences. These results are consistent with a model whereby
Chk1 dephosphorylation is regulated, at least in part, by Chk1
kinase activity.
PP2A dephosphorylates Chk1 in vivo and in vitro. Enhanced
phosphorylation of Chk1 was observed in cells treated with OA
(Fig. 4A) and OA efficiently blocked Chk1 dephosphorylation
in extracts incubated in vitro (Fig. 4B). These findings identify
the PPP family of protein phosphatases as potential Chk1
regulators because this family is sensitive to inhibition by OA
(23). The dephosphorylation of Chk1 on S317 was monitored
in extracts supplemented with additional phosphatase inhibi-
tors in order to aid in the identification of cellular phosphatases
FIG. 2. Go¨6976-induced phosphorylation of Chk1 is mediated by
ATR. (A) Asynchronously growing HeLa cells were treated with ve-
hicle (DMSO), 50 M wortmannin for 2 h, or 1 M Go¨6976 for 1 h.
HeLa cells were also pretreated with wortmannin for 2 h and then
treated with Go¨6976 for 1 h. As a positive control for wortmannin,
inhibition of Akt phosphorylation was analyzed. Western blotting was
performed with the indicated antibodies. (B) Cells expressing func-
tional ATM (ATM) or cells lacking functional ATM (ATM) were
incubated with 1 M Go¨6976 for 1 h or 2 h. Western blotting was
performed with the indicated antibodies. (C) HeLa cells were trans-
fected with 100 nM ATR-specific siRNAs or scrambled siRNAs. After
48 h, cells were treated with DMSO or 1 M Go¨6976 for 1 h and then
harvested for Western blotting with the indicated antibodies.
7532 LEUNG-PINEDA ET AL. MOL. CELL. BIOL.
 o
n
 January 10, 2014 by W
ashington University in St. Louis
http://m
cb.asm
.org/
D
ow
nloaded from
 
responsible for Chk1 dephosphorylation (Fig. 6A). Chk1 de-
phosphorylation occurred normally in extracts containing
DMSO (lane 3), Go¨6976 (lane 4), or the PP1-specific inhibitor
I-2 (lane 7). These results demonstrate that PP1 is not required
for Chk1 dephosphorylation in this assay. In contrast, fostrie-
cin (lane 6), like OA (lane 5), impaired Chk1 dephosphoryla-
tion in vitro. Fostriecin is a potent inhibitor of PP2A, PP4, and
possibly PP6; is a poor inhibitor of PP1; and does not inhibit
PP5 (6, 30, 53). Taken together, these results suggest that
PP2A, PP4, and PP6 may contribute to Chk1 dephosphoryla-
tion in vivo.
Next, the consequences of reducing levels of specific protein
phosphatases on Chk1 phosphorylation in vivo were assessed
(Fig. 6B). If Chk1 is undergoing a continual cycle of phosphor-
ylation/dephosphorylation, then enhanced Chk1 phosphoryla-
tion should be observed in vivo if the appropriate phosphatase
is knocked down. As seen in Fig. 6B, siRNAs specific for
individual protein phosphatases significantly reduced levels of
PP1 and PP2A without affecting levels of PP4 or PP6 (Fig. 6B
and C). Importantly, enhanced phosphorylation of Chk1 on
S317 and S345 was observed in PP2A-deficient cells in both the
absence and presence of Go¨6976 (Fig. 6B, lanes 3 and 6). In
contrast, knockdown of PP1 did not cause Chk1 to accumulate
in a phosphorylated form (Fig. 6B, lanes 2 and 5), confirming
that PP1 does not contribute to S317 and S345 dephosphory-
lation in vivo. Interestingly, despite the higher levels of phos-
phorylated Chk1 in PP2A-deficient cells (Fig. 6B, lanes 3 and
6), overall levels of Chk1 were reduced in these cells. To test if
phosphorylation impaired Chk1 recognition by Chk1 antibod-
ies, samples were treated with  phosphatase to dephosphor-
FIG. 3. Go¨6976 does not induce global phosphorylation of ATR targets or H2AX foci. HeLa cells were untreated (control) or were incubated
with 20 mM HU (2 h), 20 M VP-16 (4 h), 1 M Go¨6976 (1 h), or 1 M UCN-01 (2 h). Cell lysates were resolved by SDS-PAGE and subjected
to Western blotting with antibodies that recognize phosphorylated substrates of ATM/ATR (A) or phosphorylated Brca1 (B). -Catenin antibodies
were used to verify equal loading. (C) HeLa cells were treated as in panels A and B, except that cells were incubated with Go¨6976 for 1 h, 2 h,
3 h, and 6 h before harvest. Samples were analyzed by Western blotting for pS1981-ATM, pS966-Smc1, pS345-Chk1, and Chk1. (D) HeLa cells
were treated as in panel C and analyzed by indirect immunofluorescence for H2AX foci.
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ylate Chk1. Immunoblotting revealed that phosphorylated and
dephosphorylated Chk1 reacted equivalently with Chk1 anti-
bodies, allowing us to conclude that samples deficient in PP2A
had lower overall levels of Chk1 (data not shown). A recent
report by Zhang et al. (49) indicates that S345-phosphorylated
Chk1 is targeted for ubiquitin-mediated proteolysis, and this
could account for the reduced levels of Chk1 observed in
PP2A-deficient cells (49).
The level of increased Chk1 phosphorylation in cells treated
with the PP2A siRNA (Fig. 6B, lane 3) was less than that in
Go¨6976-treated cells (Fig. 6B, lane 4). If Go¨6976 acts solely by
disrupting the Chk1-PP2A regulatory circuit, then the effects
of PP2A siRNA and Go¨6976 on Chk1 phosphorylation should
be similar. The differences observed in Fig. 6B can be ac-
counted for in a couple of ways. Since PP2A acts catalytically,
the reduction in PP2A protein achieved by siRNA treatment
may not translate into a corresponding reduction in PP2A
enzymatic activity. Thus, there may not be a direct correlation
between loss of PP2A protein and increase in phospho-Chk1.
Another explanation to account for this result is that PP2A
may not be the only phosphatase that contributes to Chk1
dephosphorylation. For example, we have not ruled out a role
for PP4 or PP6—both are OA and fostriecin sensitive and both
share regulatory subunits with PP2A. In addition, PPM1D is
known to dephosphorylate Chk1 (32). Thus, levels of phosphor-
ylated Chk1 would be higher in Go¨6976-treated cells than in
PP2A-siRNA-treated cells if Go¨6976 treatment affected the
ability of phosphatases in addition to PP2A to dephosphorylate
Chk1.
Next, lysates prepared from PP2A-deficient cells were tested
for their ability to dephosphorylate Chk1 in vitro (Fig. 6C).
Dephosphorylation of Chk1 on S317 and S345 was observed in
lysates prepared from cells treated with scrambled siRNAs
(lane 2). In contrast, Chk1 remained stably phosphorylated on
S317 and S345 when incubated in OA-treated lysates (lane 1)
and PP2A-deficient lysates (lane 3). Finally, purified PP2A was
tested for its ability to directly dephosphorylate Chk1 on S317
and S345 in vitro. As seen in Fig. 6D, PP2A (lane 3) but not
PP1 (lane 2) was able to dephosphorylate Chk1 in vitro. OA
(lane 5) but not Go¨6976 (lane 4) inhibited Chk1 dephosphor-
ylation by PP2A in vitro, supporting the conclusion that
Go¨6976 is not a phosphatase inhibitor.
FIG. 4. OA impairs Chk1 dephosphorylation in vivo and in vitro.
(A) HeLa cells were untreated (lane 1) or were incubated with 20 mM
HU for 2 h to generate phosphorylated Chk1 (lanes 2 to 8). The
culture medium was then removed, and cells were incubated in com-
plete medium containing DMSO, 1 M Go¨6976, or 1 M OA. Chk1
phosphorylation was monitored at 45 min and 60 min after HU re-
moval by Western blot analysis. Alternatively, HeLa cells were incu-
bated with 1 M Go¨6976 or 1 M OA for 1 h followed by Western blot
analysis (lanes 10 and 11). (B) HeLa cells were incubated with 20 mM
HU for 2 h to generate phosphorylated Chk1. Cells were washed, and
lysates were prepared and either analyzed directly by SDS-PAGE and
Western blotting (lane 1) or were incubated in vitro in the presence of
DMSO (lane 2) or the indicated concentrations of Go¨6976 (lanes 3 to
6) or OA (lanes 7 to 11) for 30 min at 30°C. Reaction products were
resolved by SDS-PAGE, and endogenous Chk1 was monitored by
Western blotting.
FIG. 5. Kinase-inactive Chk1 exhibits higher basal phosphorylation
and slower kinetics of dephosphorylation. HeLa cells were transiently
transfected with kinase-active GFP-Chk1 or kinase-inactive GFP-
Chk1. Twenty-four hours posttransfection, cells were left untreated
(lanes 1 and 6) or were incubated with HU for 2 h. HU was removed,
and cells were harvested immediately (lanes 2 and 7) or were cultured
in complete medium for the indicated times. (A) A fraction of the cells
were lysed and analyzed by Western blotting with the indicated anti-
bodies. (B) The remaining cells were stained for DNA content, and
GFP-positive cells were analyzed by flow cytometry. The percentages
of cells in each phase of the cell cycle are indicated.
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DISCUSSION
Phosphorylation of Chk1 on S317 and/or S345 has been the
gold standard in the checkpoint field for monitoring the acti-
vation state of Chk1 in vivo (31, 50). Here we report that
S317/S345-phosphorylated Chk1 (the presumably “active”
form of Chk1) paradoxically accumulates in cells treated with
Chk1 inhibitors. The stabilization and accumulation of
Cdc25A were observed in cells treated with each Chk1 inhib-
itor, confirming that they were effective at blocking Chk1 ac-
tivity in vivo. Furthermore, we demonstrated that phosphory-
lation of Chk1 under these conditions requires ATR.
One might predict that Chk1 inhibition would elicit a check-
point response leading to activation of ATM/ATR, and this, in
turn, would lead to enhanced Chk1 phosphorylation on S317
and S345. However, Chk1 phosphorylation in response to
Chk1 inhibition was detected within 15 min of treatment with
Chk1 inhibitors (Fig. 1A), yet DNA damage, as measured by
the appearance of H2AX foci, was not detected until after 2 h
of Go¨6976 treatment (Fig. 3D). In addition, phosphorylation
FIG. 6. PP2A dephosphorylates Chk1 on S317 and S345. (A) HeLa cells were untreated (lane 1) or were incubated in the presence of HU for
2 h to induce Chk1 phosphorylation. Lysates derived from HU-treated cells were harvested immediately (lane 2) or were incubated in the presence
of DMSO (lane 3), 1 M Go¨6976 (lane 4), 1 M OA (lane 5), 0.5 M fostriecin (lane 6), or 1 M I-2 (lane 7) for 30 min at 30°C (lanes 3 to 7).
Phosphorylation of Chk1 was assayed by immunoblotting. (B) Targeted knockdown of specific protein phosphatases was accomplished by
transfecting HeLa cells with the indicated siRNAs. After 48 h, cells were either untreated (lanes 1 to 3) or were incubated with 1 M Go¨6976 for
1 h (lanes 4 to 6). Cell lysates were prepared and analyzed for phosphorylated Chk1, total Chk1, PP1, and PP2A by Western blotting using the
Femto maximum sensitivity substrate (Pierce). Short (5 s) and long (15 s) exposures of the Western blot are shown. (C) HeLa cells were transfected
with scrambled or PP2A-specific siRNAs. Lysates were prepared 48 h later and incubated in vitro with phosphorylated GFP-Chk1 for 30 min at
30°C in the presence or absence of OA. Western blotting was performed with the indicated antibodies. (D) Purified PP1 or PP2A was incubated
with phosphorylated GFP-Chk1 immunoprecipitated from HU-treated cells for 30 min at 30°C in the presence or absence of 1 M Go¨6976 or 1
M OA. Reaction products were resolved by SDS-PAGE and analyzed by Western blotting.
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of ATM/ATR targets was not readily detected in cells treated
with Chk1 inhibitors (Fig. 3). These results led us to investigate
the contribution made by protein phosphatases to Chk1 regu-
lation. Several interesting observations relevant to Chk1 de-
phosphorylation were made. First, phosphorylated Chk1 accu-
mulated in cells treated with OA while both OA and fostriecin
but not I-2 blocked Chk1 dephosphorylation in cell extracts.
Second, S317/S345-phosphorylated Chk1 accumulated in cells
where PP2A levels were reduced by siRNA treatment and
PP2A was able to directly dephosphorylate Chk1 on S317 and
S345 in vitro. Taken together, these findings argue that PP2A
regulates Chk1 in vivo. Dis2, the fission yeast homolog of PP1,
dephosphorylates S345 in fission yeast Chk1 (13) and PP1
dephosphorylates a human Chk1 S345 phosphopeptide in vitro
(32), suggesting that PP1 might regulate both fission yeast and
human Chk1. The following lines of evidence suggest that this
is not the case: I-2 failed to block human Chk1 dephosphory-
lation in vitro (Fig. 6A), PP1 knockdown resulted in a decrease
in levels of phosphorylated Chk1 in vivo (Fig. 6B), and PP1 was
incapable of dephosphorylating full-length human Chk1 on
S317 and S345 in vitro (Fig. 6D). Interestingly, PPM1D (or
Wip1) has recently been shown to dephosphorylate Chk1 on
S345 and to a lesser extent on S317 (32). PPM1D is a p53
transcriptional target gene that is insensitve to OA. Thus, in
response to DNA damage, p53 induces PPMID, which in turn
may function to return Chk1 to a hypophosphorylated state as
cells recover from checkpoint arrest. Our study indicates that
PP2A has a role distinct from that of PPM1D in that it facil-
itates Chk1 dephosphorylation in the absence of genotoxic
stress.
Given that ATR was not detectably activated in HeLa cells
treated with Chk1 inhibitors, another model to explain the
accumulation of phosphorylated Chk1 under conditions of
Chk1 inhibition would be if Chk1 inhibitors also functioned as
PP2A inhibitors. However, unlike OA, Chk1 inhibitors did not
block Chk1 dephosphorylation in cell extracts or block the
ability of PP2A to dephosphorylate Chk1 in vitro. A third
important observation made in this study is that kinase-inactive
Chk1 is phosphorylated on S317 and S345 under basal, un-
stressed conditions and its dephosphorylation occurs more
slowly than does that of wild-type Chk1. Taken together, these
results suggest a regulatory circuit whereby ATR continually
phosphorylates Chk1 on S317 and S345 and phosphorylated
“active” Chk1 in turn, either directly or indirectly, stimulates
PP2A to dephosphorylate S317 and S345 (Fig. 7). In this
model, kinase-inactive Chk1 would be unable to stimulate its
own dephosphorylation and therefore would be expected to
accumulate in a more highly phosphorylated form in vivo. We
conclude that Chk1 inhibitors disrupt the ATR/Chk1/PP2A
feedback loop by blocking PP2A “activation” by Chk1 allowing
the ATR/Chk1 phosphorylation circuit to dominate and like-
wise, phosphatase inhibitors like OA and fostriecin block the
enzymatic activity of PP2A, thereby enabling phosphorylated
Chk1 to accumulate. Future studies will focus on how Chk1
kinase activity contributes to Chk1 dephosphorylation in vivo.
Possibilities include direct activation of PP2A by Chk1 or en-
hanced recognition of phosphorylated Chk1 by PP2A. In ad-
dition, it will also be important to understand how checkpoint
activation pushes the equilibrium in favor of the ATR/Chk1
arm of the pathway and away from the Chk1/PP2A arm of the
pathway.
Interestingly, treatment of cells with increasing doses of OA
(see Fig. S1A in the supplemental material) or with a single
dose of OA for increasing periods of time (see Fig. S1B in the
supplemental material) caused phosphorylated Chk1 to accu-
mulate to higher levels than in cells treated with Go¨6976 and
to even higher levels than that of the initial phospho-Chk1 at
the start of the reaction. This suggests that, in vivo, OA stim-
ulates both the kinase and phosphatase arms of the pathway
(i.e., inhibits dephosphorylation of Chk1 and stimulates phos-
phorylation of Chk1). In contrast, treatment of cells with in-
creasing doses of Go¨6976 (see Fig. S1A in the supplemental
material) or with a single dose of Go¨6976 for increasing peri-
ods of time (see Fig. S1B in the supplemental material)
blocked dephosphorylation of Chk1, but did not stimulate
Chk1 phosphorylation above the initial phospho-Chk1 level at
the start of the reaction. This result coupled to the observation
that Go¨6976 does not activate ATR, strongly argues that
Go¨6976 regulates the phosphatase rather than the kinase arm
of the pathway. How does OA regulate the ATR-Chk1 arm of
the pathway? Chowdhury et al. (9) demonstrated that DNA
DSB repair and checkpoint recovery in vivo require dephos-
FIG. 7. The ATR-Chkl-PP2A regulatory circuit. During an unperturbed cell division cycle, Chk1 is continually being phosphorylated on S317
and S345 by ATR. However, phosphorylated Chk1 does not accumulate to any significant extent because PP2A continually dephosphorylates Chk1
on S317 and S345. Importantly, the ability of PP2A to dephosphorylate Chk1 depends, in part, on Chk1 kinase activity as chemical inhibition of
Chk1 promotes the accumulation of phosphorylated Chk1 in vivo. Thus, Chk1 promotes its own dephosphorylation during an unperturbed cell
division cycle.
7536 LEUNG-PINEDA ET AL. MOL. CELL. BIOL.
 o
n
 January 10, 2014 by W
ashington University in St. Louis
http://m
cb.asm
.org/
D
ow
nloaded from
 
phorylation of H2AX by PP2A. OA blocks H2AX dephos-
phorylation, thereby sustaining/enhancing the DNA damage
signaling pathway. These results predict that if HU-treated
cells are incubated with OA subsequent to HU removal, these
cells would fail to repair DNA DSBs and sustained incubation
in the presence of OA might lead to enhanced DNA damage
and further activation of checkpoint pathways. If this were the
case, phosphorylated Chk1 would be expected to accumulate
to higher levels than in cells treated with Go¨6976 alone be-
cause OA would not only block Chk1 dephosphorylation by
PP2A, it would also stimulate Chk1 phosphorylation by ATR.
Recent studies have uncovered important roles for serine/
threonine protein phosphatases in regulating checkpoint re-
sponses. In addition to Chk1 (this study), PP2A regulates ATM
(19, 38), Chk2 (14), and H2AX (9, 27). PP5 regulates ATM,
ATR, and DNA protein kinase signaling (2, 46, 48). Recently
the Pph3 phosphatase complex has been shown to dephosphor-
ylate H2AX in budding yeast (27). PPM1D dephosphorylates
Chk1, Chk2, and p53 (16, 32), and PP1 regulates fission yeast
Chk1 (13) and Xenopus Cdc25 (35, 36). Interestingly, OA was
shown to induce the autophosphorylation of ATM on serine
1981 in unirradiated cells, indicating that PP2A functions dur-
ing a normal cell division cycle to counteract the autoactivation
tendencies of ATM (19). Thus, PP2A functions to maintain
both ATM and Chk1 in a low-activity state during an unper-
turbed cell division cycle. In the case of ATM, PP2A counter-
acts ATM autophosphorylation, whereas in the case of Chk1,
PP2A counteracts ATR-mediated phosphorylation. The net
effect is to prevent ATM and Chk1 from relaying checkpoint
signals when cells are not experiencing genotoxic stress.
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